The AAV capsid has T=1 icosahedral symmetry and is approximately 250 Å in diameter. Its relatively small capsid size limits its genome to ∼4.7 kb, with two major open reading frames (ORFs), rep and cap. The rep ORF encodes four proteins required for genome replication and packaging. The cap ORF encodes three structural VPs, VP1, VP2, and VP3, composed of alternatively spliced mRNAs. The proteins overlap and share a common C-terminus. VP3 is approximately 61 kDa and accounts for ∼85% of the capsid protein content. The minor capsid proteins VP1 (∼87 kDa) and VP2 (∼73 kDa) contain unique N-terminal extensions (VP1u) that contain the phospholipase A2 (PLA2) domain and a nuclear localization signal (VP1/2 consensus region), respectively. According to gel densitometry, a total of 60 copies of the three VPs assembled into T=1 icosahedral particles in a ratio of 1:1:8 to 10 (VP1:VP2:VP3, respectively).
A third alternative ORF was recently discovered, located in the VP2/VP3 mRNA, encoding an assembly-activating protein that reportedly aids capsid assembly. It is believed that during the entry of AAV capsids into cells, exposure of endosomes to acidic conditions leads to conformational changes and exposure of the common region of VP1u and VP1/2, which is required for endosomal escape and nuclear entry. Interactions with cellular proteases and pH-activated autohydrolysis have also been implicated in the entry process.
In humans, deletion of SCN9A, encoding the voltage-gated sodium channel NaV1.7, results in severe pain insensitivity and anosmia. Conditional deletion of NaV1.7 in mouse sensory neurons also abolished pain, suggesting that the site of analgesia is the nociceptor. Here, researchers demonstrate through in vivo calcium imaging and extracellular recordings that NaV1.7 knockout mice have essentially normal nociceptor activity. However, glutamate and substance P release from central terminals of spinal nociceptors is greatly reduced by an opioid-dependent mechanism. The analgesic effect was also significantly reversed by central rather than peripheral application of opioid antagonists. In contrast, the lack of neurotransmitter release from olfactory sensory neurons was not associated with opioids. Male and female humans with NaV1.7 null mutations exhibit reversible analgesia with naloxone. Thus, opioid-dependent inhibition of neurotransmitter release is the primary mechanism of NaV1.7 null analgesia in mice and humans.
Here, despite altered distributions of cold and mechanical responses, the researchers used calcium imaging to find little evidence of reduced nociceptor excitability in animals lacking NaV1.7, with no changes in peak response amplitude to any stimulus, the prevalence of multimodality, or the number of noxious heat responses. Broadly similar results were obtained by calcium imaging in WT and KOAdv mice that virally expressed GCaMP6f (Figure 1A-D).
Figure 1. In vivo calcium imaging of NaV1.7-deficient sensory neurons virally expressing GCaMP6f. (A) Confocal z-stacks of DRGs in vivo from NaV1.7 KOAdv mice that virally expressed GCaMP6f. AAV1-CAG-GCaMP6f was injected intraperitoneally into P2 mouse pups. (B) Bar graphs summarizing the distribution of all sensory neurons that responded to different noxious stimuli in WT and KOAdv animals. These animals have significantly fewer cells that respond to cold compared to Pirt-GCaMP3 mice, likely due to biased expression of virally delivered GCaMP6f. (D) Bar graph showing similar prevalence of multimodal nociceptors in WT and KOAdv mice. (E-F) Scatter plots showing similar peak calcium responses (ΔF/F0) elicited by different noxious stimuli in WT and KOAdv. (MacDonald D I, et al., 2020)
Customer Reviews
Versatile Application
The versatility of AAV1-CAG-GCaMP6f is outstanding. We have successfully applied it in diverse experimental setups, from in vivo imaging in rodent models to in vitro assays in primary cultured neurons.
Write a Review